James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Forget Walmart and Target — Costco ‘Gets It’

Investors often argue about whether Walmart or Target is the better buy. Well, stop your bickering -- the real top discount retail stock is Costco.

A Dark Horse Threatens to Win the Mobile Payment Race

After years of frustration with mobile payment options, Walmart, Target, Sears and other retailers are close to unleashing their own application, MCX.

Is M&A Mania Poised to Keep Fanning the Market’s Flames?

America's renewed push of merger & acquisition action has the potential to drive market optimism and help buoy stocks -- but which stocks, and for how long?

4 High-Fliers That Could Crash-Land Soon

2013 has been a very good year for some high-profile companies. In fact, for a few of these stocks, this year has been a little too good.

VeriFone Can’t Win For Losing

VeriFone plunged 20% on Thursday on a pretty spectacular earnings miss. But until the company gets a new CEO to push a major turnaround, that'll only be the start.

Monster Beverage’s Surprising Swing: Not All That Surprising

The moral of the MNST story? The news only matters when it matters, and a stock’s price is frequently little more than a reflection of public opinion.

Sleepy Amerco Is Packing In the Profits

Amerco -- perhaps better known as U-Haul -- has doubled in the past year ... and the ride's far from over.

It’s Hard to Win the Pharma News Game

Big news for three cancer-treatment drugs had virtually zero effect on the stocks. Here's why investors shouldn't have been surprised, and what they can learn.

Will ‘Sell in May and Go Away’ Take Hold in 2013 After All?

S&P 500 charts from the past decade illustrate why we shouldn't start panicking about the recent market turbulence.

4 Questionable Hedge Fund Picks From Q1

The nation's biggest hedge funds disclosed their first-quarter buys and sells, with some reminding us that even the pros can sometimes choose poorly.